News
Premature_baby

AZ, Sanofi build case for one-shot RSV antibody

A pooled analysis of data for AstraZeneca and Sanofi's respiratory syncytial virus (RSV) antibody nirsevimab has concluded that the drug is almost 80% effective at preventing lower respirat

Debates & Insights

News

Press Releases

Newsletters and Deep Dive
digital magazine

Views & Analysis

Webinars

Podcasts

Video

White Papers

Event

Partner Content

Debates & Insight